Patent details
EP3169345
Title:
HIGH PURITY ORITAVANCIN AND METHOD OF PRODUCING SAME
Basic Information
- Publication number:
- EP3169345
- PCT Application Number:
- US2015040736
- Type:
- European Patent Granted for LU
- Legal Status:
- Unitary Effect Registered
- Application number:
- EP158215897
- PCT Publication Number:
- WO2016011245
- First applicant's nationality:
- Translation Language:
- EPO Publication Language:
- English
- English Title of Invention:
- HIGH PURITY ORITAVANCIN AND METHOD OF PRODUCING SAME
- French Title of Invention:
- ORITAVANCINE À HAUTE PURETÉ ET SON PROCÉDÉ DE PRODUCTION
- German Title of Invention:
- HOCHREINES ORITAVANCIN UND VERFAHREN ZUR HERSTELLUNG DAVON
- SPC Number:
-
Unitary Effect
- Unitary Effect Requested:
- Yes
- Unitary Effect Request Filing Date:
- 29/01/2025
- Link to UPP Register:
-
European Patent Register
- Unitary Effect Request Withdrawal Date:
-
- Unitary Effect Status:
- Unitary Effect Registered
- Unitary Effect Acceptance Decision Date:
- 05/02/2025
- Unitary Effect Rejection Decision Date:
-
- Unitary Effect Date:
- 29/01/2025
- Unitary Effect Registration Date:
- 05/02/2025
- Unitary Effect Re-establishment of rights Filing Date:
-
- Unitary Effect Re-establishment of rights EPO Decision :
-
- Unitary Effect Re-establishment of rights EPO Decision Date:
-
- Explanatory Text UE:
-
- Safety Net Request Date:
- Safety Net Decision Date:
- Safety Net Decision Outcome:
- SPC Number:
-
Dates
- Filing date:
- 16/07/2015
- Grant date:
- 29/01/2025
- EP Publication Date:
- 24/05/2017
- PCT Publication Date:
- 21/01/2016
- Claims Translation Received Date:
- Translations Received Date (B1 EP Publication):
- Translations Received Date (B2 EP Publication):
- Translations Received Date (B3 EP Publication):
- Publication date:
- 29/01/2025
- EP B1 Publication Date:
- 29/01/2025
- EP B2 Publication Date:
- EP B3 Publication Date:
- Lapsed date:
- Expiration date:
- 16/07/2035
- Renunciation date:
- Revocation date:
- Annulment date:
Owner
- From:
- 22/01/2025
-
-
- Name:
- Melinta Therapeutics, LLC
- Address:
- 389 Interpace Parkway
Suite 450, Parsippany, NJ 07054, United States (US)
Inventor
1
- Name:
- RAFAI FAR, Adel
- Address:
- Canada (CA)
2
- Name:
- KNABLE, Carl M.
- Address:
- United States (US)
3
- Name:
- DING, Min
- Address:
- United States (US)
4
- Name:
- REAMER, Douglas M.
- Address:
- United States (US)
5
- Name:
- KRISHNA, Gopal
- Address:
- United States (US)
6
- Name:
- PRUYNE, Julie J.
- Address:
- United States (US)
7
- Name:
- PETZEL, James P.
- Address:
- United States (US)
8
- Name:
- CHEMBURKAR, Sanjay R.
- Address:
- United States (US)
Priority
- Priority Number:
- 201462025737 P
- Priority Date:
- 17/07/2014
- Priority Country:
- United States (US)
Classification
- IPC classification:
-
A61K 38/14;
A61K 31/7052;
A61K 47/36;
A61K 47/30;
A61K 47/26;
A61K 9/19;
C07K 9/00;
C12P 21/02;
A61P 31/04;
Publication
European Patent Bulletin
1
- Issue number:
- 202505
- Publication date:
- 29/01/2025
- Description:
- Grant (B1)
2
- Issue number:
- 202510
- Publication date:
- 05/03/2025
- Description:
- Unitary Effect Request Receipt
3
- Issue number:
- 202511
- Publication date:
- 12/03/2025
- Description:
- Unitary Effect Request Acceptance
Annual Fees
- Annual Fee Due Date:
-
- Annual Fee Number:
-
- Expected Payer:
-
- Last Annual Fee Payment Date:
-
- Last Annual Fee Paid Number:
-
- Payer:
-
Filing date |
Document type |
Number of pages |